A new study suggests that radiation prior to CAR-T infusion is a safe bridging therapy — and this approach may even decrease some of the immunotherapy’s side effects, researchers hypothesize.
An analysis showed that outcomes of SARS-CoV-2 infections can be disproportionately mild in some patient cohorts.
An analysis finds that mortality rates for NSCLC are falling faster than incidence rates, which the authors attributed to the introduction of targeted therapies in 2013.
Localized prostate cancer is thought to metastasize by tapping into a developmental program used by its embryonic ancestors.
Sustained remission of CLL is associated with enrichment of a less-differentiated, early-memory phenotype of T cells in the apheresis product used to make CAR-T therapies.
Infections often precede a formal diagnosis of CLL. Researchers found that antimicrobial use began to rise 6 years prior to CLL diagnosis.
Upfront metastasis-directed therapy may be a viable treatment approach in patients with oligorecurrent disease, particularly those who wish to defer systemic therapy.
Men with GPS scores greater than 40 had a poor disease prognosis after surgery and their disease was likely to behave like that of high-risk patients.
A study suggested that the immunotherapy could be sensitizing non-Hodgkin lymphoma patients to subsequent therapies.
Enrichment of an early memory CD8+ T-cell phenotype in patients’ blood was predictive of their response to CAR-T therapy in CLL, NHL, and MM.
